← ALNYLAM PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $47.2m | $89.9m | $74.9m | $219.8m | $492.9m | $844.3m | $1.0b | $1.8b | $2.2b | $3.7b | |
| Cost of Revenue | $6.8m | $13.0m | $1.8m | $25.1m | $78.1m | $115.0m | $140.2m | $268.2m | $306.5m | $677.2m | |
| Gross Profit (Calculated) (derived) | $40.4m | $77.0m | $73.1m | $194.7m | $414.8m | $729.3m | $897.2m | $1.6b | $1.9b | $3.0b | |
| Operating Expenses | $471.7m | $590.0m | — | — | — | — | — | — | — | — | |
| Operating Income (Loss) | ($424.6m) | ($500.1m) | ($814.7m) | ($939.4m) | ($828.4m) | ($708.7m) | ($785.1m) | ($282.2m) | ($176.9m) | $501.6m | |
| Additional Financial Items | |||||||||||
| Gain (Loss) Related to Litigation Settlement | — | — | $20.6m | $0 | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($350.7m) | ($378.3m) | ($573.2m) | ($597.6m) | ($682.9m) | ($794.7m) | ($1.1b) | ($450.3m) | ($571.9m) | $18.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($410.1m) | $500.1m | ($760.7m) | ($885.3m) | ($855.6m) | ($852.1m) | ($1.1b) | ($433.5m) | ($377.4m) | $323.2m | |
| Investment Income, Net | $8.3m | $12.2m | $29.3m | $33.4m | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Parent | ($410.1m) | ($490.9m) | ($761.5m) | ($886.1m) | ($858.3m) | ($852.8m) | ($1.1b) | ($440.2m) | ($278.2m) | $313.7m | |
| Earnings Per Share, Basic | — | — | — | ($8.11) | ($7.46) | ($7.20) | ($9.30) | ($3.52) | ($2.18) | $2.39 | |
| Earnings Per Share, Diluted | ($4.79) | ($5.42) | ($7.57) | ($8.11) | ($7.46) | ($7.20) | ($9.30) | ($3.52) | ($2.18) | $2.33 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 109.3m | 115.0m | 118.5m | 121.7m | 124.9m | 127.7m | 131.0m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 109.3m | 115.0m | 118.5m | 121.7m | 124.9m | 127.7m | 134.7m | |
| Research and Development Expense | $382.4m | $390.6m | $505.4m | $655.1m | $654.8m | $792.2m | $883.0m | $1.0b | $1.1b | $1.3b | |
| General and Administrative Expense | $89.4m | $199.4m | — | — | — | — | — | — | — | — | |
| Selling, General and Administrative Expense | $89.4m | $199.4m | $382.4m | $479.0m | $588.4m | $620.6m | $770.7m | $795.6m | $975.5m | $1.2b | |
| Other Nonoperating Income (Expense) | $6.2m | ($3.0m) | $4.2m | $11.3m | $45.5m | ($2.0m) | ($109.4m) | ($125.7m) | ($180.6m) | $5.2m | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $141.9m | $252.6m | |
| Costs and Expenses | — | — | $889.6m | $1.2b | $1.3b | $1.6b | $1.8b | $2.1b | $2.4b | $3.2b | |
| Current Income Tax Expense (Benefit) | — | — | $1.6m | $2.8m | $5.9m | $3.4m | $5.6m | $7.4m | $7.5m | $11.6m | |
| Interest Expense | — | — | $0 | $0 | $84.5m | $143.0m | $156.0m | $121.2m | $141.9m | $252.6m | |
| Operating Lease, Expense | — | — | — | — | $50.7m | $59.5m | $58.6m | $61.6m | — | — | |
| Income Tax Expense (Benefit) | — | — | $823k | $863k | $2.7m | $680k | $4.2m | $6.7m | ($99.2m) | $9.4m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.